inluriyo

Generic: imlunestrant

Labeler: eli lilly and company
NDC Directory HUMAN PRESCRIPTION DRUG NDA Inactive Finished

Drug Facts

Product Profile

Brand Name inluriyo
Generic Name imlunestrant
Labeler eli lilly and company
Dosage Form TABLET, FILM COATED
Routes
ORAL
Active Ingredients

imlunestrant 200 mg/1

Manufacturer
Eli Lilly and Company

Identifiers & Regulatory

Product NDC 0002-1717
Product ID 0002-1717_1ece6e73-2242-434e-b297-7ccf07a54c1e
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category NDA
Application Number NDA218881
Listing Expiration 2027-12-31
Marketing Start 2025-09-25

Pharmacologic Class

Established (EPC)
estrogen receptor antagonist [epc]
Mechanism of Action
estrogen receptor antagonists [moa] p-glycoprotein inhibitors [moa] breast cancer resistance protein inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 00021717
Hyphenated Format 0002-1717

Supplemental Identifiers

RxCUI
2725917 2725923
UNII
9CXQ3PF69U
NUI
N0000175582 N0000000145 N0000185503 N0000190113

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name inluriyo (source: ndc)
Generic Name imlunestrant (source: ndc)
Application Number NDA218881 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 200 mg/1
source: ndc
Packaging
  • 28 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28)
  • 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56)
  • 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61)
source: ndc

Packages (3)

0002-1717-28 28 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28) 0002-1717-56 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56) 0002-1717-61 56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61)

Ingredients (1)

imlunestrant (200 mg/1)

Linked Drug Pages (1)

Inluriyo ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["ORAL"], "spl_id": "1ece6e73-2242-434e-b297-7ccf07a54c1e", "openfda": {"nui": ["N0000175582", "N0000000145", "N0000185503", "N0000190113"], "unii": ["9CXQ3PF69U"], "rxcui": ["2725917", "2725923"], "spl_set_id": ["5bc172e4-e8a2-441a-be52-279a7f890196"], "pharm_class_epc": ["Estrogen Receptor Antagonist [EPC]"], "pharm_class_moa": ["Estrogen Receptor Antagonists [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]"], "manufacturer_name": ["Eli Lilly and Company"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "28 TABLET, FILM COATED in 1 BOTTLE (0002-1717-28)", "package_ndc": "0002-1717-28", "marketing_start_date": "20251016"}, {"sample": false, "description": "56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-56)", "package_ndc": "0002-1717-56", "marketing_start_date": "20251015"}, {"sample": true, "description": "56 TABLET, FILM COATED in 1 BOTTLE (0002-1717-61)", "package_ndc": "0002-1717-61", "marketing_start_date": "20251113"}], "brand_name": "Inluriyo", "product_id": "0002-1717_1ece6e73-2242-434e-b297-7ccf07a54c1e", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Estrogen Receptor Antagonist [EPC]", "Estrogen Receptor Antagonists [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "0002-1717", "generic_name": "imlunestrant", "labeler_name": "Eli Lilly and Company", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Inluriyo", "active_ingredients": [{"name": "IMLUNESTRANT", "strength": "200 mg/1"}], "application_number": "NDA218881", "marketing_category": "NDA", "marketing_start_date": "20250925", "listing_expiration_date": "20271231"}